Tranexamic Acid in Hip and Knee Arthroplasty

J. Stuart Melvin, Louis S. Stryker, Rafael J. Sierra

Research output: Contribution to journalReview article

46 Citations (Scopus)

Abstract

Perioperative blood loss is a significant concern for patients undergoing total joint arthroplasty. A growing body of evidence has shown tranexamic acid (TXA) to be effective in decreasing perioperative blood loss and transfusion requirements in both primary and revision hip and knee arthroplasty. TXA is a synthetic drug that limits blood loss through inhibition of fibrinolysis and clot degradation. Both topical and intravenous administration of TXA, in a variety of dosing regimens, has proven effective. Further investigation is required to determine the optimal dose and dosing regimens; however, evidence exists to recommend an initial intravenous dose be given before beginning the procedure, with at least one additional intravenous dose administered postoperatively. Additionally, topical TXA doses >2 g appear to be more efficacious than lower doses. Finally, relatively few adverse reactions have been reported in arthroplasty patients, and no study to date has demonstrated an increased risk of symptomatic venous thromboembolic events in this patient population.

Original languageEnglish (US)
Pages (from-to)732-740
Number of pages9
JournalJournal of the American Academy of Orthopaedic Surgeons
Volume23
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Tranexamic Acid
Knee Replacement Arthroplasties
Hip
Arthroplasty
Topical Administration
Fibrinolysis
Blood Transfusion
Intravenous Administration
Joints
Pharmaceutical Preparations
Population

Keywords

  • hip arthroplasty
  • knee arthroplasty
  • Tranexamic acid

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Tranexamic Acid in Hip and Knee Arthroplasty. / Melvin, J. Stuart; Stryker, Louis S.; Sierra, Rafael J.

In: Journal of the American Academy of Orthopaedic Surgeons, Vol. 23, No. 12, 01.12.2015, p. 732-740.

Research output: Contribution to journalReview article

Melvin, J. Stuart ; Stryker, Louis S. ; Sierra, Rafael J. / Tranexamic Acid in Hip and Knee Arthroplasty. In: Journal of the American Academy of Orthopaedic Surgeons. 2015 ; Vol. 23, No. 12. pp. 732-740.
@article{cf225d28fef44fabb9091f7ccab72e3a,
title = "Tranexamic Acid in Hip and Knee Arthroplasty",
abstract = "Perioperative blood loss is a significant concern for patients undergoing total joint arthroplasty. A growing body of evidence has shown tranexamic acid (TXA) to be effective in decreasing perioperative blood loss and transfusion requirements in both primary and revision hip and knee arthroplasty. TXA is a synthetic drug that limits blood loss through inhibition of fibrinolysis and clot degradation. Both topical and intravenous administration of TXA, in a variety of dosing regimens, has proven effective. Further investigation is required to determine the optimal dose and dosing regimens; however, evidence exists to recommend an initial intravenous dose be given before beginning the procedure, with at least one additional intravenous dose administered postoperatively. Additionally, topical TXA doses >2 g appear to be more efficacious than lower doses. Finally, relatively few adverse reactions have been reported in arthroplasty patients, and no study to date has demonstrated an increased risk of symptomatic venous thromboembolic events in this patient population.",
keywords = "hip arthroplasty, knee arthroplasty, Tranexamic acid",
author = "Melvin, {J. Stuart} and Stryker, {Louis S.} and Sierra, {Rafael J.}",
year = "2015",
month = "12",
day = "1",
doi = "10.5435/JAAOS-D-14-00223",
language = "English (US)",
volume = "23",
pages = "732--740",
journal = "Journal of the American Academy of Orthopaedic Surgeons",
issn = "1067-151X",
publisher = "American Association of Orthopaedic Surgeons",
number = "12",

}

TY - JOUR

T1 - Tranexamic Acid in Hip and Knee Arthroplasty

AU - Melvin, J. Stuart

AU - Stryker, Louis S.

AU - Sierra, Rafael J.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Perioperative blood loss is a significant concern for patients undergoing total joint arthroplasty. A growing body of evidence has shown tranexamic acid (TXA) to be effective in decreasing perioperative blood loss and transfusion requirements in both primary and revision hip and knee arthroplasty. TXA is a synthetic drug that limits blood loss through inhibition of fibrinolysis and clot degradation. Both topical and intravenous administration of TXA, in a variety of dosing regimens, has proven effective. Further investigation is required to determine the optimal dose and dosing regimens; however, evidence exists to recommend an initial intravenous dose be given before beginning the procedure, with at least one additional intravenous dose administered postoperatively. Additionally, topical TXA doses >2 g appear to be more efficacious than lower doses. Finally, relatively few adverse reactions have been reported in arthroplasty patients, and no study to date has demonstrated an increased risk of symptomatic venous thromboembolic events in this patient population.

AB - Perioperative blood loss is a significant concern for patients undergoing total joint arthroplasty. A growing body of evidence has shown tranexamic acid (TXA) to be effective in decreasing perioperative blood loss and transfusion requirements in both primary and revision hip and knee arthroplasty. TXA is a synthetic drug that limits blood loss through inhibition of fibrinolysis and clot degradation. Both topical and intravenous administration of TXA, in a variety of dosing regimens, has proven effective. Further investigation is required to determine the optimal dose and dosing regimens; however, evidence exists to recommend an initial intravenous dose be given before beginning the procedure, with at least one additional intravenous dose administered postoperatively. Additionally, topical TXA doses >2 g appear to be more efficacious than lower doses. Finally, relatively few adverse reactions have been reported in arthroplasty patients, and no study to date has demonstrated an increased risk of symptomatic venous thromboembolic events in this patient population.

KW - hip arthroplasty

KW - knee arthroplasty

KW - Tranexamic acid

UR - http://www.scopus.com/inward/record.url?scp=84948125778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948125778&partnerID=8YFLogxK

U2 - 10.5435/JAAOS-D-14-00223

DO - 10.5435/JAAOS-D-14-00223

M3 - Review article

VL - 23

SP - 732

EP - 740

JO - Journal of the American Academy of Orthopaedic Surgeons

JF - Journal of the American Academy of Orthopaedic Surgeons

SN - 1067-151X

IS - 12

ER -